Skip to main content

Table 2 Adjusted HbA1c reduction over 12 months in patients switching from NPH to glargine*

From: Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study

Variable

Type 1 (n = 304)

Type 2 (n = 397)

No.

Δ HbA 1c (%)

p-value†

No.

Δ HbA 1c (%)

p-value†

Overall

304

-0.38

<0.001

397

-0.31

<0.001

HbA1c by baseline level

      

   ≥ 7%

259

-0.42

<0.001

327

-0.36

<0.001

   ≥ 8%

186

-0.57

<0.001

271

-0.47

<0.001

   ≥ 9%

107

-0.96

<0.001

162

-0.69

<0.001

   ≥ 10%

53

-1.07

<0.001

71

-0.97

<0.001

  1. *Adjusted for significantly correlated demographic and clinical covariates including concomitant use of bolus, age, weight, hypoglycaemia, and baseline HbA1c (in the 3 months prior to insulin initiation).
  2. †p-values by the paired t-test for difference in mean HbA1c following switch from NPH to glargine.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840